Outpatient Pulmonary Allergy & Asthma Clinical Pathway

In-Room Step-by-Step Clinical Approach

Outpatient Pulmonary Evaluation

Structured 5-step workflow for evaluating asthma, allergic rhinitis, skin allergies, and selecting safe diagnostic testing and treatment in an outpatient pulmonary clinic.

Triage & Red-Flag Safety Screen

Airway stability: Check baseline SpO2, wheeze, and recent SABA/OCS bursts. Defer SPT or SCIT if asthma is uncontrolled.
Medication audit: Screen for beta-blockers, ACE inhibitors, antihistamines, TCAs, and topical steroids at test sites.
Anaphylaxis history: Prior severe reaction, mast cell disorder, or cardiovascular disease elevates risk.

Caution: Continue inhaled asthma controllers before SPT.

Phenotype & Diagnostic Selection

Respiratory: Spirometry w/ BD + FeNO + CBC w/ diff (AEC) + Total IgE.
Allergen sensitization: Choose SPT (fast, 15–20 min) if washout met & skin clear; choose Serum sIgE if on antihistamines, dermatographism, eczema, or high anaphylaxis risk.
Contact skin rash: Order Patch Testing (Type IV delayed hypersensitivity).

Positive thresholds: SPT ≥3 mm wheal; sIgE ≥0.35 kUA/L.

Targeted First-Line Treatment

Asthma (GINA): Track 1 ICS-formoterol MART; avoid SABA-only therapy.
Allergic Rhinitis: Intranasal corticosteroid (INCS) ± intranasal antihistamine (azelastine).
Atopic Dermatitis: Daily emollients + topical corticosteroid / calcineurin inhibitor.
Chronic Urticaria: 2nd-gen H1 antihistamine (up-titrate to 4x daily if refractory).

Verify inhaler technique & adherence at every visit.

Step-Up: Biologics & Immunotherapy

Severe T2 Asthma: Match biomarker (IgE/perennial allergy → Omalizumab; AEC/FeNO → Dupilumab, Mepolizumab, Benralizumab; Broad → Tezepelumab).
Refractory CSU / AD: Omalizumab (CSU); Dupilumab / JAKi (AD).
Disease-modifying AIT: SCIT (in-office, 30-min wait) or SLIT tablets (1st dose in-office, prescribe epinephrine).

Omalizumab carries FDA Black Box Warning for anaphylaxis (>0.2%).

Complication Monitoring, Post-Test Wait & Charting

Mandatory Observation: 20–30 min post-SPT; strict 30 min post-SCIT (delayed SRs >30 min still represent 27%–50% of reactions).
Anaphylaxis First-Line: IM Epinephrine 1:1000 (0.01 mg/kg, max 0.5 mg adult) anterolateral thigh q5–15 min + recumbent position (avoid upright posture).

Secondary Agents: O2, IV 0.9% NS, albuterol for bronchospasm, H1/H2 blockers for comfort (never delay epinephrine).
Charting: Document Dx, ICD-10, wheal/flare vs sIgE values, observation time, and hyphenated plan.

| |

Asthma & Respiratory Allergy Management

Aligned with GINA 2025/2026 Strategy Reports and AAAAI/ACAAI Rhinitis & Immunotherapy Practice Parameters.

Allergic Rhinitis (J30.1 / J30.89)

Step 1 (Classify): Intermittent (<4 d/wk or <4 wk/yr) vs Persistent (≥4 d/wk and ≥4 wk/yr); Mild vs Moderate-Severe (sleep/work/asthma impact).
Step 2 (First-Line): Intranasal corticosteroid (fluticasone, mometasone, budesonide) + saline irrigation. Add intranasal antihistamine (azelastine/olopatadine) for rapid breakthrough.
Step 3 (Adjuncts): Non-sedating oral 2nd-gen antihistamine (cetirizine, fexofenadine, loratadine). Limit topical oxymetazoline to ≤3–5 days (rebound rhinitis medicamentosa).
Step 4 (AIT): Refer/initiate SCIT or SLIT if refractory or patient seeks disease modification.

Asthma Stepwise Care (GINA 2025/2026)

Step 1–2 (Track 1 Preferred): As-needed low-dose ICS-formoterol (reduces severe exacerbations vs SABA alone).
Step 3: Low-dose maintenance + reliever ICS-formoterol (MART).
Step 4: Medium-dose ICS-formoterol MART. Check adherence, inhaler technique, triggers (rhinitis, GERD, allergens).
Step 5 (Severe Asthma): High-dose ICS-LABA ± LAMA (tiotropium). Phenotype with blood eosinophils (AEC), FeNO, Total IgE, SPT/sIgE → add targeted biologic.

Biologics & Immunotherapy: Indications, Complications & Risk Factors

Therapy	Target / Biomarker	Key Complications & Rates	Risk Factors & Cautions
Omalizumab (Xolair)	Anti-IgE; perennial aeroallergen + IgE 30–700 IU/mL (asthma) or CSU	Anaphylaxis (FDA Black Box): <0.1% in premarketing trials; >0.2% in FDA post-marketing surveillance.	Prior anaphylaxis, initial 3 doses require in-office observation; prescribe epinephrine autoinjector.
Dupilumab (Dupixent)	Anti-IL-4Rα; AEC ≥150 or FeNO ≥25 ppb, OCS-dependent, AD, CRSwNP	Conjunctivitis/ocular surface symptoms, transient hypereosinophilia, injection-site reactions.	Monitor for eosinophilic vasculitis (EGPA) if tapering OCS; avoid live vaccines.
Mepolizumab / Benralizumab	Anti-IL-5 / IL-5Rα; severe eosinophilic asthma (AEC ≥150–300)	Mepolizumab: no anaphylaxis in clinical trials; low hypersensitivity. (Reslizumab IV: 0.3% anaphylaxis).	Screen/treat pre-existing helminth infections; consider varicella vaccination if non-immune.
Tezepelumab (Tezspire)	Anti-TSLP; severe asthma (T2-high or T2-low, no biomarker floor)	Pharyngitis, arthralgia, back pain; rare hypersensitivity reactions.	Avoid abrupt OCS/ICS withdrawal; screen for helminth infection.
SCIT (Allergy Shots)	Allergic rhinitis / mild-mod controlled allergic asthma	Systemic reactions: 0.095%–0.24% per injection visit (1 in 424 to 1 in 1,047). Delayed SRs (>30 min): 27%–50% of all SRs.	Uncontrolled asthma (contraindication), beta-blockers, ACEi, buildup phase, peak pollen season. Mandatory 30-min wait.
SLIT (Sublingual Tablets)	Grass, ragweed, dust mite allergic rhinitis	Local oral pruritus/edema (common); rare systemic anaphylaxis (lower than SCIT).	First dose in-office w/ 30-min observation; prescribe home epinephrine autoinjector; hold for oral ulcers/dental work.

Skin Allergies: Step-by-Step Outpatient Management

Based on 2023 AAAAI/ACAAI Joint Task Force Atopic Dermatitis Guidelines, Contact Dermatitis Practice Parameter, and Urticaria guidelines.

Atopic Dermatitis (L20.9)

JTF 2023

Step 1 (Barrier): Liberal fragrance-free emollients/ointments immediately post-bathing; avoid harsh soaps.
Step 2 (Topical Anti-Inflammatory): Topical corticosteroids (low potency face/folds; mid-high potency trunk/extremities) or topical calcineurin inhibitors (tacrolimus/pimecrolimus) for steroid-sparing maintenance.
Step 3 (Adjuncts): Bleach baths or topical crisaborole/ruxolitinib for mild-moderate flares; treat secondary S. aureus superinfection.
Step 4 (Systemic): Moderate-severe refractory AD → Dupilumab, tralokinumab, or oral JAK inhibitors (upadacitinib, abrocitinib).

Complications/Risks: Skin atrophy/striae from prolonged potent TCS; dupilumab conjunctivitis; JAKi infection/thrombosis/lipid risks. Avoid routine food elimination diets without true IgE-mediated allergy.

Allergic Contact Dermatitis (L23.9)

Type IV

Step 1 (Exposure History): Map distribution (eyelids, hands, neck) + occupational/avocational/cosmetic exposures (nickel, fragrances, preservatives, rubber).
Step 2 (Acute Control): Mid-to-high potency topical corticosteroid; short oral prednisone taper (14–21 days) if severe/widespread (>20% BSA, e.g., poison ivy) to prevent rebound.
Step 3 (Patch Testing): Indicated for chronic/recurrent dermatitis when ACD is suspected (history alone has ~76% sensitivity/specificity).
Step 4 (Avoidance): Provide safe-product lists excluding identified haptens.

Complications/Risks: Short (<7 day) oral steroid courses cause rebound flare; patch testing causes local irritation/angry back syndrome if placed on active dermatitis.

Chronic Spontaneous Urticaria (L50.1)

>6 Weeks

Step 1 (Screen): Confirm wheals last <24h without bruising/hyperpigmentation (if >24h or painful, biopsy for urticarial vasculitis). Check NSAID/ACEi triggers.
Step 2 (First-Line): Standard-dose 2nd-gen non-sedating H1 antihistamine (cetirizine, fexofenadine, loratadine).
Step 3 (Up-titrate): Increase 2nd-gen H1 antihistamine up to 4x standard daily dose if persistent after 2–4 weeks.
Step 4 (Biologic): Add Omalizumab 300 mg SC q4wk if antihistamine-refractory; cyclosporine if omalizumab fails.

Complications/Risks: Avoid chronic systemic steroids; omalizumab anaphylaxis (>0.2% post-marketing); sedation/anticholinergic effects if 1st-gen H1 used.

Respiratory & Allergy Testing: SPT vs. Serum sIgE

Step-by-step protocol and medication washout requirements per AAAAI/ACAAI Practice Parameters & AAOA/Baylor guidelines.

Skin Prick Testing (SPT) — Step-by-Step

Step 1 (Pre-check): Confirm stable asthma, no beta-blocker/antihistamine interference, intact volar forearm/upper back skin.
Step 2 (Prep): Clean skin with alcohol, allow to dry, mark grid (≥2 cm spacing to avoid cross-contamination).
Step 3 (Apply): Place allergen drops + Histamine positive control (10 mg/mL) + Saline negative control. Prick epicutaneously with lancet/multi-test device (avoid bleeding).
Step 4 (Read at 15–20 min): Measure longest wheal diameter (mm). Positive = wheal ≥3 mm larger than negative control.
Step 5 (Observe): Monitor patient 20–30 min post-testing; wipe allergens off.

Risks: Rare systemic reaction (higher with intradermal testing). Never perform intradermal testing without prior negative SPT.

Serum Specific IgE (sIgE) Labs — When to Choose

No washout needed: Ideal when patient cannot stop antihistamines or tricyclic antidepressants.
Skin conditions: Extensive eczema/atopic dermatitis, severe dermatographism, or active urticaria.
Safety contraindications to SPT: Uncontrolled/brittle asthma, recent anaphylaxis, pregnancy (relative), or non-stop beta-blocker therapy.
Threshold: Detection typically ≥0.35 kUA/L (correlate with clinical history; sensitization ≠ clinical allergy).
Complications: Venipuncture bruising/vasovagal only; zero systemic allergic risk.

Pre-SPT Medication Washout & Hold Guide

Medication Class	Examples	Recommended Hold	Clinical Note
2nd / 3rd Gen Oral Antihistamines	Cetirizine, fexofenadine, loratadine, desloratadine, levocetirizine	5–7 days	Suppresses histamine wheal/flare (false negative).
1st Gen Oral Antihistamines	Diphenhydramine, hydroxyzine, chlorpheniramine, brompheniramine	3–5 days	Check OTC cold/flu/sleep meds for hidden antihistamines.
H2 Receptor Blockers	Famotidine, cimetidine	2 days (48 hr)	Modest cutaneous H2 suppression.
Antihistamine Nasal / Eye Drops	Azelastine, olopatadine, ketotifen	1–3 days	Systemic absorption can blunt SPT.
Tricyclic / Atypical Antidepressants	Doxepin, amitriptyline, mirtazapine	7–14 days (if safe)	Potent H1 blockade. Do not stop without prescriber clearance; use sIgE instead.
Topical Corticosteroids (Test Site)	Triamcinolone, clobetasol, hydrocortisone	Up to 21 days	Hold on test area only; may use unaffected skin or sIgE.
Beta-Blockers (Oral / Eye Drops)	Metoprolol, propranolol, timolol	Safety Caution	Blunts epinephrine response if anaphylaxis occurs. Prefer serum sIgE.
Asthma Inhalers & Montelukast	ICS, ICS-LABA, albuterol, montelukast, INCS	DO NOT HOLD	Continue all asthma controllers; montelukast does not suppress SPT.

Outpatient Pulmonary Clinic Supplies & Risk-Minimization Cautions

Minimum equipment, medications, and protocols required on-site before performing SPT, SCIT, or biologic administration.

Mandatory Emergency Anaphylaxis Kit (AAAAI/ACAAI)

Epinephrine 1:1000 (1 mg/mL): Vials + 1 mL syringes w/ 23G 1-inch needles (or autoinjectors 0.3 mg adult / 0.15 mg peds). Dose: 0.01 mg/kg IM anterolateral thigh (max 0.5 mg adult), q5–15 min PRN.
Oxygen & Airway: O2 cylinder/wall source, non-rebreather mask, nasal cannula, bag-valve-mask (BVM), oral/nasal airways.
Monitoring & IV: Pulse oximeter, BP cuff, stethoscope, AED, IV catheters, 0.9% Normal Saline bags & tubing.
Bronchodilator: Albuterol nebulizer solution + compressor/O2 tubing (or MDI + spacer).
Second-Line Meds: Diphenhydramine (IM/IV/PO), Famotidine (H2 blocker), Methylprednisolone / Prednisone (never delay epinephrine for these).

SPT & Immunotherapy Procedure Supplies

Skin Testing: Standardized allergen extracts, Histamine positive control (10 mg/mL), Saline negative control, single-prick lancets or multi-test applicators, skin marker, mm wheal ruler, 15–20 min timer, alcohol swabs, tissues.
Storage (Extracts): Dedicated medical refrigerator at 2°C–8°C (35.6°F–46.4°F) with digital min/max thermometer. Never freeze (destroys allergen potency).
SCIT Administration: 0.3–1.0 mL allergy syringes (26G–27G 3/8"–1/2"), two-identifier patient verification, dose-adjustment log (local reaction/missed dose/new vial).
Observation Area: Seating within direct line-of-sight of clinical staff for mandatory 30-minute post-injection wait.

Critical Risk-Minimization Cautions for Outpatient Pulmonology

Check Asthma Control First: Never administer SCIT or SPT during an acute asthma flare or if PEF/FEV1 is significantly below baseline.
Recumbent Positioning: During acute anaphylaxis, lay patient flat (supine) with legs elevated; upright/sitting posture risks "empty heart" PEA arrest.

Physician Presence: A physician or qualified advanced practitioner trained in anaphylaxis management must be immediately available on-site during all SPT/SCIT/in-office biologic doses.
Biphasic & Delayed Risk: Educate patients on delayed reactions (>30 min) and ensure prescribed epinephrine autoinjector is carried to every SCIT/SLIT/omalizumab visit.

Exact Medications, Adult Dosages & Linked References

Quick-reference outpatient pulmonary dosing tables grounded in AAAAI/ACAAI Practice Parameters, GINA 2025, and FDA Prescribing Information.

1. Emergency Anaphylaxis Kit (In-Office)

Medication	Adult Dosage & Route	Reference
Epinephrine (1:1,000 / 1 mg/mL)	0.01 mg/kg (max 0.5 mg) IM anterolateral thigh q5–15 min PRN; autoinjector 0.3 mg IM (peds 15–30 kg: 0.15 mg)	AAAAI/ACAAI 2020 • StatPearls
Albuterol (Bronchospasm Adjunct)	Nebulizer or MDI via spacer PRN after epinephrine	AAAAI/ACAAI 2020 • RECAPEM
Diphenhydramine (H1 Adjunct)	25–50 mg PO/IM/IV q4–6h PRN (second-line for urticaria/pruritus; never delay epinephrine)	RECAPEM • Nursing CE
Famotidine (H2 Adjunct)	20 mg IV q12h or 20–40 mg PO BID (second-line adjunct)	RECAPEM • ESSI Protocol
Methylprednisolone (Adjunct)	125 mg IV (for prolonged/asthma-associated reactions; does not prevent biphasic anaphylaxis)	AAAAI/ACAAI 2020 • Nursing CE

2a. Asthma Maintenance & Rescue Inhalers

Medication	Adult Dosage & Route	Reference
Budesonide-Formoterol (MART)	160/4.5 mcg 1–2 inhalations BID + 1 inhalation PRN (max 640/18 mcg/day maintenance; up to 12 total inhalations/day short-term)	GINA 2025 • Symbicort PI
Fluticasone-Salmeterol (Advair Diskus)	100/50, 250/50, or 500/50 mcg: 1 inhalation BID (rinse mouth after use; not for acute bronchospasm)	DailyMed • FDA Label
Fluticasone Furoate-Vilanterol (Breo Ellipta)	100/25 or 200/25 mcg: 1 inhalation once daily (max 200/25 mcg/day; rinse mouth after use)	DailyMed
Fluticasone-Umeclidinium-Vilanterol (Trelegy Ellipta)	100/62.5/25 or 200/62.5/25 mcg: 1 inhalation once daily (ICS/LAMA/LABA; rinse mouth after use)	DailyMed
Tiotropium (Spiriva Respimat)	1.25 mcg/actuation: 2 inhalations (2.5 mcg) once daily (add-on LAMA for uncontrolled asthma)	Drugs.com Monograph • AAP Drug Lookup
Albuterol-Budesonide (Airsupra)	180/160 mcg (2 actuations of 90/80 mcg) PRN asthma symptoms (max 6 doses / 12 inhalations per 24h)	DailyMed • FDA Label

2b. Severe Asthma Biologic Selection Algorithm (GINA 2025/2026 & ERS/ATS)

GINA Severe Asthma Guide | ERS/ATS Biomarker Guideline

Step 1: Confirm & Phenotype

Verify severe asthma on high-dose ICS-LABA, inhaler technique, and adherence. Measure Blood Eosinophils (AEC), FeNO, Total IgE, and Perennial Aeroallergen SPT/sIgE.

Step 2: Match Endotype

Allergic IgE-driven (perennial SPT/sIgE + IgE 30–700): Omalizumab
Eosinophilic IL-5 (AEC ≥150–300; 1st-line if >1,500): Mepolizumab / Benralizumab
T2-High IL-4/13 (AEC 150–1,500 or FeNO ≥25 ppb, OCS-dep, AD/CRSwNP): Dupilumab
T2-Low / Any Biomarker: Tezepelumab

Step 3: 16–24 Wk Reassessment

Target ≥50% exacerbation reduction, ≥100 mL FEV1 gain, ACT improvement, or OCS taper. If non-responder after 4–6 months, re-check biomarkers and switch pathway.

2c. Biologics: Starting Doses, Predictors & Clinical Cautions

Biologic & Class	Starting & Maintenance Dose	Clinical Insights & Cautions	Reference
Omalizumab (Xolair) Anti-IgE	Asthma: 75–375 mg SC q2wk or q4wk (0.016 mg/kg per IU/mL IgE table). CSU: 150 or 300 mg SC q4wk (IgE/weight independent).	Predictors: AEC ≥260/μL, FeNO ≥19.5 ppb, childhood-onset allergy, comorbid CSU. Caution: FDA Black Box Warning for anaphylaxis (>0.2% post-marketing). Observe in-office (2h for 1st 3 doses / 30m thereafter per GINA/label) & prescribe epinephrine autoinjector.	FDA Label • ERS/ATS
Dupilumab (Dupixent) Anti-IL-4Rα	Asthma: 400 mg SC load → 200 mg SC q2wk. OCS-dep Asthma / AD / CRSwNP: 600 mg SC load → 300 mg SC q2wk.	Predictors: AEC 150–1,500/μL, FeNO ≥25 ppb, OCS dependence, comorbid AD or CRSwNP. Caution: Avoid if baseline AEC >1,500/μL; monitor for transient hypereosinophilia/EGPA when tapering OCS, conjunctivitis/keratitis (~10% in AD), and avoid live vaccines.	PMC9960148 • MDPI Review
Mepolizumab (Nucala) Anti-IL-5	Asthma (≥12y): 100 mg SC q4wk (no loading dose).	Predictors: AEC ≥150–300/μL, frequent exacerbations, adult-onset eosinophilic asthma, nasal polyps. Caution: Very low hypersensitivity (no anaphylaxis in clinical trials); screen/treat pre-existing helminth infections and consider varicella vaccination if non-immune.	PMC9960148 • PMC8175040
Benralizumab (Fasenra) Anti-IL-5Rα	Asthma: 30 mg SC q4wk for first 3 doses, then 30 mg SC q8wk.	Insights: Induces direct NK-cell ADCC eosinophil depletion; convenient q8wk maintenance. Caution: Screen/treat helminth infections before initiation; monitor for rare hypersensitivity reactions; do not abruptly stop systemic/inhaled steroids.	PMC9960148 • MDPI Review
Tezepelumab (Tezspire) Anti-TSLP	Asthma (≥12y): 210 mg SC q4wk (no loading dose).	Insights: First biologic approved regardless of T2 biomarker status (effective in T2-low and T2-high severe asthma). Caution: Avoid live attenuated vaccines; screen helminth infections; monitor pharyngitis/arthralgia and avoid abrupt OCS withdrawal.	FDA Label • PMC12773671

3. Allergic Rhinitis

Medication	Adult Dosage & Route	Reference
Fluticasone Propionate (INCS)	2 sprays (100 mcg) per nostril once daily (total 200 mcg/day); may step down to 1 spray/nostril daily	GlobalRPH • GoodRx
Azelastine (Intranasal Antihistamine)	0.1% (137 mcg/spray): 1–2 sprays per nostril q12h (or 2 sprays/nostril once daily)	MIMS • GoodRx
Azelastine-Fluticasone (Combo)	137/50 mcg: 1 spray per nostril BID	DailyMed
Cetirizine (2nd-Gen Oral H1)	10 mg PO once daily	Allergy Asthma Proc
Montelukast (LTRA)	10 mg PO once daily in the evening (reserve in AR for inadequate response/intolerance to alternatives; FDA Boxed Warning)	FDA Boxed Warning • DailyMed

4. Skin Allergies (Atopic Dermatitis & Chronic Spontaneous Urticaria)

Medication	Adult Dosage & Route	Reference
2nd-Gen H1 Antihistamine (CSU)	Standard daily dose (e.g., cetirizine 10 mg daily), up-titrated up to 4x standard daily dose if refractory	AAAAI/ACAAI • Dermatology Times
Omalizumab (CSU)	150 mg or 300 mg SC q4wk (independent of serum IgE or weight)	Xolair FDA Label • PMC8654989
Dupilumab (Atopic Dermatitis)	600 mg SC load (two 300 mg injections), then 300 mg SC q2wk	MedCentral • PMC6110636
Tacrolimus Ointment (AD)	0.03% or 0.1%: Apply thin layer BID to face/neck/intertriginous areas	PMC6110636 • AAAAI/ACAAI AD 2023
Topical Corticosteroids (AD)	Apply 1–2x daily (short-term bursts ≤4 weeks; potency matched to body site)	PMC6110636 • AAAAI/ACAAI AD 2023

Outpatient Pulmonary Allergy & Asthma Guide